Combinations ; See Below
| Brand Name | Manufacturer Name | Distributor | Drug Strength | Packaging | Formulation | Formulation Strength | Price |
|---|---|---|---|---|---|---|---|
| Ivermectol | Ochoa Laboratories Ltd. | Medisel Kenya Ltd | 3mg | 10 | Tablet | per tablet | KES 1,516.00 |
| Ivermectol | Ochoa Laboratories Ltd. | Medisel Kenya Ltd | 6mg | 10 | Tablet | per tablet | KES 2,602.00 |
| Ivermectin More info | |
|---|---|
| Mode Of Action | ivermectin binds selectively to glutamate-gated chloride ion channels in invertebrate muscle and nerve cells of the microfilaria. This binding causes an increase in the permeability of the cell membrane to chloride ions and results in hyperpolarization of the cell, leading to paralysis and death of the parasite. It also acts as an agonist of the neurotransmitter gamma-aminobutyric acid (GABA), thereby disrupting GABA-mediated central nervous system (CNS) neurosynaptic transmission. |
| Drug Indication | Onchocerciasis, Strongyloidiasis, Bancroftian filariasis and Scabies |
| Contra-Indications | Hypersensitive to any components of the formulation. |
| Side Effects | Ophthalmologic effect like limbitis, punctate opacity, conjunctivitis, and eyelid edema; Mazzotti-like reaction; pruritus; tachycardia; facial edema; headache; peripheral edema; diarrhoea; dizziness; skin rash; itching; postural hypotension; anorexia; somnolence; tremor. |
| Dosage | Onchocerciasis: 150mcg/kg as a single dose. The dose may be repeated every 3 to 12 months, depending on the recurrence of symptoms and/or microfilariae. Strongyloidiasis: 200mcg/kg as a single dose. Bancroftian filariasis: 20 - 200 mcg/kg as a single dose. Scabies: 150 mcg/kg as a single dose for one treatment (repeated after 2 weeks in immunocompromised patients). |
| Pregnancy Category | Category B3 |
| Pregnancy Category Description | Drugs which have been taken by only a small number of pregnant women and women of child-bearing age with no any established rise in the frequency of malformations or other direct or indirect detrimental effects on the foetus having been noted. Studies in animals show evidence of an increased occurrence of foetal damage, the significance of which is uncertain in human |
| Drug Category | DRUGS ACTING ON INFECTIONS |
| Drug Sub-Category | Schistosomicides |